GlassScriptPhysician profile
Kimberly Lafferty
NPI 1376978221
$2,681.37
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,575 · 2022: $1,054 · 2023: $51.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.81 | 2021-2022 | |
| Abbott Laboratories | $372.37 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $295.93 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.49 | 2021-2022 | |
| Amarin Pharma, INC. | $142.03 | 2021-2022 | |
| Abbvie INC. | $128.19 | 2021-2022 | |
| Amgen INC. | $116.41 | 2021 | |
| Lilly USA, LLC | $115.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $98.41 | 2021-2022 | |
| Lifescan, INC. | $88.16 | 2021-2022 | |
| Radius Health, INC. | $75.32 | 2021-2022 | |
| Medtronic, INC. | $75.30 | 2021-2023 | Minimed 770g |
| Zealand Pharma US, INC. | $65.16 | 2021-2022 | |
| Mannkind Corporation | $52.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $45.07 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $39.51 | 2022 | |
| Cequr Corporation | $36.25 | 2021-2022 | |
| Clarus Therapeutics INC. | $34.37 | 2021 | |
| Ibsa Pharma INC. | $32.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.00 | 2022 | |
| Nevro Corp. | $28.00 | 2022 | |
| Becton, Dickinson and Company | $19.39 | 2021 | |
| Intuity Medical INC | $18.47 | 2022 | |
| Acerus Pharmaceuticals Corporation | $17.11 | 2021 | |
| Recordati_rare_diseases_inc. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.